Drug lookup | Fillwise

TERBINAFINE HCL

All products: not a benefit

Lamisil · DIN 02031116 · 250mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-03-14 — choose a marketed DIN from the same-category list.Discontinued 2025-03-14 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-03-14 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2025-03-14 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Lamisil · DIN 02031116 Manufacturer: Novartis Pharma Canada Inc.; listing date 2007-12-19 Health Canada: Cancelled post market since 2025-03-14 · brand LAMISIL · ATC D01BA02 TERBINAFINE · form Tablet · route Oral · ingredients TERBINAFINE (TERBINAFINE HYDROCHLORIDE) 250 MG · company Novartis pharmaceuticals canada inc · schedule Prescription

Check this DIN again · Health Canada product record

Lamisil: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13990 · Verify on the e-Formulary ↗ (DIN 02031116)

Source record

DIN 02031116: Lamisil Raw flags: notABenefit=Y, sec3=Y Item: 081204016; group id 16; item number 0021; lccId None; manufacturer id NOV Source form: Tab; strength: 250mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02031116 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13990

Interchangeable products

Apo-Terbinafine · DIN 02239893 · $0.7714 Auro-Terbinafine · DIN 02320134 · $0.7714 Co Terbinafine · DIN 02254727 · $0.7714 PMS-Terbinafine · DIN 02294273 · $0.7714 Terbinafine · DIN 02353121 · $0.7714 Terbinafine · DIN 02385279 · $0.7714 Teva-Terbinafine · DIN 02240346 · $0.7714

Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02031116

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2025-03-14 — choose a marketed DIN from the same-category list.

Other drugs in the same formulary class (08:12:04 Antifungals) and how they are covered

Matched class: 08:12:04 Antifungals

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMPHOTERICIN B Some products covered without a code (check the product listing): FLUCONAZOLE, ITRACONAZOLE, KETOCONAZOLE, NYSTATIN 08:12:04 Antifungals

AMPHOTERICIN B

· 1 products · General benefit · strengths: · Inj Pd-50mg Pk

FLUCONAZOLE

· 17 products · Limited Use, codes 528 (1), Listed, not a benefit (2), General benefit (14) · strengths: 10mg/mL, 50mg, 100mg · O/L, Tab

ITRACONAZOLE

· 5 products · General benefit (2), Listed, not a benefit (1), Limited Use, codes 570 (2) · strengths: 100mg, 10mg/mL · Cap, Oral Sol

KETOCONAZOLE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 200mg · Tab

NYSTATIN

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 100000U/mL · O/L

VORICONAZOLE

· 6 products · Limited Use, codes 399 · strengths: 50mg, 200mg · Tab

CASPOFUNGIN ACETATE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg/Vial · Inj-Vial Pk

MICAFUNGIN SODIUM

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg/Vial, 100mg/Vial · Inj Pd-10mL Vial Pk

POSACONAZOLE

· 7 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 40mg/mL · DR Tab, O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:04

Full class listing Related classes: 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.

What the Health Canada label says it is for

1 INDICATIONS LAMISIL® (terbinafine hydrochloride) is indicated for:  the treatment of fungal infections of the skin and nails caused by dermatophytes such as Trichophyton (e.g. T. rubrum, T. mentagrophytes, T. verrucosum, T. violaceum), Microsporum canis, Epidermophyton floccosum and yeasts of the genus Candida (eg. C. albicans), as well as Malassezia furfur. LAMISIL tablets:  the treatment of onychomycosis (fungal infection of the nail) caused by dermatophyte fungi. o Prior to initiating treatment with LAMISIL® tablets, appropriate nail or skin specimens should be obtained for laboratory testing (KOH preparation, fungal culture, or nail biopsy) in order to confirm the diagnosis of onychomycosis or dermatomycosis.  may be considered for the treatment of severe tineal skin infections (tinea corporis, tinea cruris and tinea pedis) which have been unresponsive to topical treatment. Note: LAMISIL tablets are not effective in pityriasis versicolor (also known as Tinea versicolor). LAMISIL cream and spray:  Cream o the treatment of fungal infections of the skin caused by dermatophytes such as tric… https://pdf.hres.ca/dpd_pm/00067056.PDF PM date: December 31, 1993 Source product: LAMISIL; DIN 02031094; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Lamisil · DIN 02031116 Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02031116

Check this DIN again

Other review policies

For Lamisil: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote

Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote

Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026